Geninus, a leading company in precision medicine and bio data-driven artificial intelligence (AI) solutions, led by CEO Park Woongyang, announced on November 12 that it has signed a supply agreement for its genome AI analysis platform 'IntelliMed™' with a major domestic biotech company.
Through this agreement, AI-based research and development collaboration in the domestic pharmaceutical and biotech industries is expected to accelerate, speeding up the commercialization of genome data analysis technology.
Geninus provides precision analysis services throughout the entire R&D process of pharmaceutical companies by combining large-scale genomic spatial omics data with AI analysis technology through its proprietary 'IntelliMed' platform. 'IntelliMed' is an integrated platform that supports everything from new drug target discovery and candidate validation to patient group classification and clinical trial design. By enabling data-driven decision-making, it enhances the efficiency and success rate of drug development.
As more pharmaceutical companies are directly utilizing AI platforms in their actual R&D processes, Geninus's genome AI analysis technology is now considered to be on a commercial trajectory. The company stated that, with this agreement, not only will the application scope of 'IntelliMed' expand, but there is also a high possibility of joint research with global pharmaceutical companies.
In addition to 'IntelliMed', Geninus also operates a spatial multi-omics based analysis platform called 'SPACEINSIGHT™'. By combining high-resolution spatial analysis technology with AI models, the company has established technological credibility with pharmaceutical companies both domestically and internationally. Recently, demand for collaboration has been increasing in overseas markets such as Japan, and this agreement is being highlighted as a case of industrial field validation for domestic AI precision analysis technology.
Park Woongyang, CEO of Geninus, said, "This agreement is evidence that Geninus's genome AI platform is providing real value at the forefront of drug development," adding, "We will further advance our precision analysis technology to the level of global pharmaceutical standards and expand strategic partnerships with bio companies both in Korea and abroad."
An industry insider commented, "This collaboration signals the entry of domestic AI precision analysis platforms into the commercialization stage," adding, "As next-generation bioinformatics technologies such as genomics and spatial omics become core tools in drug development, Geninus's technological capabilities are leading to tangible results in data-driven drug discovery."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
